Track topics on Twitter Track topics that are important to you
Terumo has received exclusive global development and commercialization rights to Orchestra BioMed’s Virtue SEB for percutaneous coronary interventions. Virtue SEB is claimed to be the first and only
The post Terumo to develop and commercialise Orchestra BioMed’s Virtue SEB appeared first on NS Medical Devices.
Original Article: Terumo to develop and commercialise Orchestra BioMed’s Virtue SEBNEXT ARTICLE